

PHARMACIST PERSPECTIVES

Exploring the Evolving Role of BTK Inhibitors in CLL

References and Suggested Readings

- Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. *Blood Adv.* 2019;3(9):1553–1562.
- Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. *Cancer.* 1981;48(1):198–206.
- Bond DA, Woyach JA. Targeting BTK in CLL: beyond ibrutinib. *Curr Hematol Malig Rep.* 2019;14(3):197–205.
- Brown JR. How I treat CLL patients with ibrutinib. *Blood.* 2018;131(4):379–386.
- Brown JR. Inherited predisposition to chronic lymphocytic leukemia. *Expert Rev Hematol.* 2008;1(1):51–61.
- Brown JR, Eichhorst BF, Ghia P, et al. A phase 3 trial comparing the efficacy and safety of acalabrutinib in combination with venetoclax with or without obinutuzumab, compared with investigator's choice of chemoimmunotherapy in patients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutation. Abstract 4318. Presented at: ASH Annual Meeting; December 9, 2019; Orlando, Florida.
- Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. *Leukemia.* 2020;34(3):787–798.
- Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. *Trends Immunol.* 2013;34(12):592–601.
- Burger JA, O'Brien S. Evolution of CLL treatment—from chemoimmunotherapy to targeted and individualized therapy. *Nat Rev Clin Oncol.* 2018;15(8):510–527.
- Byrd JC, et al. Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: updated results from the phase 1/2 ACE-CL-001 study. Abstract 692. Presented at: ASH 60th Annual Meeting; December 1–4, 2018; San Diego, California.
- Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. *N Engl J Med.* 2016;374(4):323–332.
- Byrd JC, Hillmen P, O'Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. *Blood.* 2019;133(19):2031–2042.
- Byrd JC, Smith S, Wagner-Johnston N, et al. First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL [published correction appears in *Oncotarget.* 2019;10(38):3827–3830]. *Oncotarget.* 2018;9(16):13023–13035.
- CHA₂DS₂-VASc/HAS-BLED/EHRA atrial fibrillation risk score calculator. CHADSVASC.org website. <https://www.chadsvasc.org/>. Accessed March 2020.
- Coutre SE, Byrd JC, Hillmen P, et al. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. *Blood Adv.* 2019;3(12):1799–1807.
- Davids NS, Brown JR. Targeting the B-cell receptor pathway in chronic lymphocytic leukemia. *Leuk Lymphoma.* 2012;53(12):2362–2370.
- Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med.* 2000;343(26):1910–1916.
- Drug development and drug interactions: table of substrates, inhibitors and inducers. U.S. Food and Drug Administration website. December 2019. <https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers>. Accessed March 2020.



PHARMACIST PERSPECTIVES

Exploring the Evolving Role of BTK Inhibitors in CLL

FDA Approved Drug: acalabrutinib. U.S. Food and Drug Administration website. November 2019.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf. Accessed March 2020.

FDA Approved Drug: ibrutinib. U.S. Food and Drug Administration website. November 2019.

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/205552x029,210563s004lbl.pdf. Accessed March 2020.

FDA Approved Drug: obinutuzumab. U.S. Food and Drug Administration website. November 2017.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125486s017s018lbl.pdf. Accessed March 2020.

FDA Approved Drug: venetoclax. U.S. Food and Drug Administration website. July 2019.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208573s011s014s015lbl.pdf. Accessed March 2020.

Finnes HD, Chaffee KG, Call TG, et al. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. *Leuk Lymphoma*. 2017;58(6):1376–1383.

Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting Conditions. *N Engl J Med*. 2019;380(23):2225–2236.

Framingham Heart Study AF score (10-year-risk). Framingham Heart Study website.

<https://www.framinghamheartstudy.org/fhs-risk-functions/atrial-fibrillation-10-year-risk/>. Accessed March 2020.

Furman RR, Wierda WG, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: 42-month follow-up of a phase 2 study. Abstract 3039. Presented at: ASH Annual Meeting; December 8, 2019; Orlando, Florida.

Gentile M, Cutrona G, Neri A, et al. Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages. *Haematologica*. 2009;94(6):887–888.

Ghia P, Pluta A, Wach M, et al. ASCEND phase 3 study of acalabrutinib vs investigator's choice of rituximab plus idelalisib (IDR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Abstract LB2606. Presented at: 24th Congress of European Hematology Association; June 16, 2019; Amsterdam, the Netherlands.

Gribben JG, Bosch F, Cymbalista F, et al. Optimizing outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. *Br J Haematol*. 2018;180(5):666–679.

Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. *Blood*. 2013;122(23):3723–3734.

Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood*. 2018;131(25):2745–2760.

Jain N, Keating MJ, Thompson PA, et al. Combined ibrutinib and venetoclax for first-line treatment for patients with chronic lymphocytic leukemia (CLL). Abstract 34. Presented at: ASH Annual Meeting; December 7, 2019; Orlando, Florida.

Jain N, Keating MJ, Thompson PA, et al. Combined ibrutinib and venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Abstract 359. Presented at: ASH Annual Meeting; December 8, 2019; Orlando, Florida.



PHARMACIST PERSPECTIVES

Exploring the Evolving Role of BTK Inhibitors in CLL

Lampson BL, Tyekucheva S, Crombie JL, et al. Preliminary safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL). Abstract 32. Presented at: ASH Annual Meeting; December 7, 2019; Orlando, Florida.

Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. *Nature*. 2015;526(7574):525–530.

Moreno C, Greil R, Demirkiran F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2019;20(1):43–56.

Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. *Am J Hematol*. 2019;94(12):1353–1363.

National Comprehensive Cancer Network. NCCN guidelines: chronic lymphocytic leukemia/small lymphocytic lymphoma. Version 4.2020; December 20, 2019. NCCN website.
https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf. Accessed March 2020.

Nosari A. Infectious complications in chronic lymphocytic leukemia. *Mediterr J Hematol Infect Dis*. 2012;4(1):e2012070.

O'Brien SM, Byrd JC, Hillmen P, et al. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: phase 3 analysis. *Am J Hematol*. 2019;94(5):554–562.

Owen C, Berinstein NL, Christofides A, et al. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. *Curr Oncol*. 2019;26(2):e233–e240.

Reiff SD, Mantel R, Smith LL, et al. The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and richter transformation. *Cancer Discov*. 2018;8(10):1300–1315.

Rogers KA, Thompson PA, Allan JN, et al. Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). *J Clin Oncol*. 2019;37(15_suppl):7530–7530.

Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular toxicities associated with ibrutinib. *J Am Coll Cardiol*. 2019;74(13):1667–1678.

SEER cancer stat facts: leukemia—chronic lymphocytic leukemia (CLL). National Cancer Institute website.
<https://seer.cancer.gov/statfacts/html/clly.html>. Accessed March 2020.

Seiler T, Döhner H, Stilgenbauer S. Risk stratification in chronic lymphocytic leukemia. *Semin Oncol*. 2006;33(2):186–194.

Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. *N Engl J Med*. 2019;381(5):432–443.

Sharman JP, Banerji V, Fogliatto LM, et al. ELEVATE TN: phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naïve chronic lymphocytic leukemia (CLL). Abstract 4318. Presented at: ASH Annual Meeting; December 7, 2019; Orlando, Florida.

Shatzel JJ, Olson SR, Tao DL, et al. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. *J Thromb Haemost*. 2017;15(5):835–847.

Singh SP, Rip J, Hendricks RW. Targeting Bruton's tyrosine kinase expression levels through microRNAs in chronic lymphocytic leukemia treatment. *Transl Cancer Res*. 2017;6(suppl 3):S502–S507.

Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. *Blood*. 2019;133(12):1298–1307.



PHARMACIST PERSPECTIVES

Exploring the Evolving Role of BTK Inhibitors in CLL

- Stühlinger MC, Weltermann A, Staber P, et al. Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. *Wien Klin Wochenschr.* 2020;132(3-4):97–109.
- Tam CS, Robak T, Ghia P, et al. Efficacy and safety of zanubrutinib in patients with treatment-naïve chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) with del(17p): initial results from arm C of the Sequoia (BGB-3111-304) trial. Abstract 499. Presented at: ASH Annual Meeting; December 7, 2019; Orlando, Florida.
- Ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in chronic lymphocytic leukemia: implications for disease pathogenesis and treatment. *Biochim Biophys Acta.* 2016;1863(3):401–413.
- Ten Hacken E, Gounari M, Ghia P, Burger JA. The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. *Leukemia.* 2019;33(2):287–298.
- U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0; November 27, 2017. National Cancer Institute website. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed March 2020.
- Wiczer TE, Levine LB, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. *Blood Adv.* 2017;1(20):1739–1748.
- Wiestner A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. *Haematologica.* 2015;100(12):1495–1507.
- Woyach JA. Ibrutinib and *Aspergillus*: a BTK-targeted risk. *Blood.* 2018;132(18):1869–1870.
- Woyach JA, et al. A phase 1 dose escalation study of ARQ 531 in selected patients with relapsed or refractory hematologic malignancies. Abstract PF355. Presented at: the 23rd Congress of European Hematology Association; June 15, 2018; Stockholm, Sweden.
- Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. *N Engl J Med.* 2014;370(24):2286–2294.
- Woyach JA, Ruppert AS, Guinn D, et al. BTK^{C481S}-mediated resistance to ibrutinib in chronic lymphocytic leukemia. *J Clin Oncol.* 2017;35:1437–1443.
- Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. *N Engl J Med.* 2018;379(26):2517–2528.
- Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. *J Hematol Oncol.* 2016;9:21.
- Yeung CCS, Shadman M. How to choose the best treatment and testing for chronic lymphocytic leukemia in the tsunami of new treatment options. *Curr Oncol Rep.* 2019;21(8):74.

